Navigation Links
Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®
Date:9/19/2011

IRVINE, California and AMSTERDAM, September 19, 2011 /PRNewswire/ --

Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online in Breast Cancer Research and Treatment, a peer-reviewed publication. BluePrint is a part of Agendia's Symphony™ suite of breast cancer products, a comprehensive collection of genetic assays that help address complex treatment decisions for any type and stage of breast cancer. The article notes that, when used in combination with Agendia's FDA-cleared MammaPrint® recurrence test, BluePrint provides an additional level of understanding for physicians, classifying breast cancer patients into Basal-type, Luminal-type A and B, and HER2-type subgroups. Recently, the expert panel at the 12th St. Gallen International Breast Cancer Conference (2011) recommended specific treatments for those particular breast cancer subtypes.

"This article illustrates the vital role of molecular subtyping in the treatment decision process for breast cancer patients. The combination of Symphony's MammaPrint and BluePrint micro-array assays provides physicians with unprecedented insight into their patient's tumor," said Dr. Bernhard Sixt, Agendia's CEO and co-founder. "From just one biopsy sample, Agendia's Symphony suite of tests provides clear insight into who to treat and how to treat them, helping to identify the optimal treatment tailored to each patient's individual needs and genetics."

The article describes molecular subtyping of breast cancer patients as "…important for the proper selection of therapy, as tumors with seemingly similar histopathological features can have strikingly different clinical outcomes." Further, the use of BluePrint may improve clinical management of breast cancer patients by identifying those patients who are mos
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
(Date:12/24/2014)... 23, 2014  Medical Science Liaisons play a large ... between the medical device industry and key stakeholders, the ... coming years as the device industry relies on them ... research by benchmarking firm, Best Practices, LLC, one area ... edge is by harnessing new technology to enable education. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
(Date:12/24/2014)... Over 700 toys, that’s what ... That is 700 smiling little faces this holiday that ... $6000 in monetary donations was given to the various ... expenses they incur through the year. Some of the ... Child's Haven , Shrine's Children's Hospitals, Toys for Tots ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... 25, 2014 Today, UWDress.com, the famous women’s ... wedding gowns, and launched a site-wide wedding gown promotion. ... wedding gowns in a more unexpected way, the collection should ... popular in the global market, and they are available with ... are offered at discounted prices, up to 75% off; most ...
(Date:12/24/2014)... BambooIndustry.com a famous bamboo flooring company offering bamboo flooring ... announces its multiple layer bamboo panel board collection , ... , Bamboo panel is the product made from 100 ... board features high quality selective bamboo and eco-friendly adhesives ... panel consists of multiple layers of bamboo. , According ...
(Date:12/24/2014)... A new, injectable weight-loss drug has been approved by ... on Tuesday approved Saxenda (liraglutide) for adults who are ... at least one weight-related health condition, such as high ... Patients taking the drug, made by Novo Nordisk, should ... FDA noted. "Obesity is a public health concern ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... Negative pressure wound therapy is a new innovation in treating ... for frequent and stressful dressing changes. A new study ... a wide range of applications with children, and can be ... a vacuum system which applies negative suction pressure to the ...
... Bereaved families of firefighters who lost their lives to work- ... relief at last. Ontarios new labor laws state that they ... in order to qualify for compensation due the dead workers ... identify eight types of cancer that will be presumed to ...
... Service, an agency of the New York state government has ... County Hospital as a shameful "chamber of filth, decay, ... Civil Liberties Union, the agency has filed a suit in ... the ward, where patients are subjected to overcrowded conditions, physical ...
... is recalling half-gallon packages of Galliker's Acidophilus Plus Reduced ... milk may be unsafe. It has not been shown ... the raw milk itself to determine the presence or ... is free of infectious organisms. Only products with the ...
... An oral vaccine can prevent mice from developing a brain ... will be presented at the American Academy of Neurology's ... 2007. Prion diseases, which include scrapie, mad cow disease, and ... or cure. ,The disease spreads when an animal ...
... Coast Eagles star Ben Cousins broke his silence for the first ... that he has indeed a problem of substance abuse. ... rehabilitation centre for the past months. He was being treated for ... ,He did not disclose the name of the drug ...
Cached Medicine News:Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 3Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Cousins Recovering from His Substance Abuse Problem 2
... CellTracks® Analyzer II is ... used to enumerate fluorescently ... immunomagnetically selected and aligned. ... the CellTracks® Analyzer II, ...
... These unique Acid Fast ... sputum smear with appropriate background ... containing a positive and negative ... Kinyoun (Cat. No. 353), Ziehl-Neelsen ...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
Medicine Products: